








isease-type natriuretic peptide levels predict outcome after
eonatal cardiac surgery
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doi:10.1016/j.jtcvs.2007.04.017bjectives: Neonates undergoing cardiac surgery are at high risk for adverse
utcomes. B-type natriuretic peptide is used as a biomarker in patients with cardiac
isease, but the predictive value of B-type natriuretic peptide after cardiac surgery
n neonates has not been evaluated. Therefore, the objective of this study was to
etermine the predictive value of perioperative B-type natriuretic peptide levels for
ostoperative outcomes in neonates undergoing cardiac surgery.
ethods: Plasma B-type natriuretic peptide determinations were made before and 2,
2, and 24 hours after surgery in 36 consecutive neonates. B-type natriuretic peptide
evels and changes in perioperative B-type natriuretic peptide were evaluated as
redictors of postoperative outcome.
esults: B-type natriuretic peptide levels at 24 hours were lower than preoperative
evels (24-h/pre B-type natriuretic peptide ratio 1) in 29 patients (81%) and higher
24-h/pre B-type natriuretic peptide ratio  1) in 7 patients (19%). A 24-hour/pre
-type natriuretic peptide level of 1 or greater was associated with an increased
ncidence of low cardiac output syndrome (100% vs 34%, P  .002) and fewer
entilator-free days (17  13 days vs 26  3 days, P  .002), and predicted the
-month composite end point of death, an unplanned cardiac operation, or cardiac
ransplant (57% vs 3%, P .003). A 24-hour/pre B-type natriuretic peptide level of
or greater had a sensitivity of 80% and a specificity of 90% for predicting a poor
ostoperative outcome (P  .003).
onclusion: In neonates undergoing cardiac surgery, an increase in B-type natri-
retic peptide 24 hours after surgery predicts poor postoperative outcome.
urgical repair or palliation of congenital cardiac defects is performed rou-
tinely in the neonatal period. Neonates, in comparison with infants and
children, have adverse events more often and have greater perioperative
ortality. Although risk-adjustment scoring systems and various biomarkers have
een investigated, it remains difficult to identify individual neonates with an
ncreased risk for poor postoperative outcome.1,2
B-type natriuretic peptide (BNP) is a 32-amino acid polypeptide hormone, with
iuretic, natriuretic, and vasoactive properties, that is used as a biomarker for the
anagement of cardiac disease in both adult and pediatric patients.3-7 We reportedecently that BNP levels predict the development of both low cardiac output
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Dyndrome (LCOS) and prolonged mechanical ventilation in
hildren with congenital heart defects amenable to biven-
ricular repair.8 However, the clinical predictive value 
erioperative BNP levels in neonates, who are most at risk
or unpredictable adverse outcomes, especially neonates
ndergoing a palliative modified Norwood stage I proce-
ure, is unknown.
Therefore, the objectives of our study were (1) to deter-
ine and compare perioperative BNP levels in neonates
ndergoing surgical repair or palliation of their cardiac
efects and (2) to investigate the potential predictive value
f BNP levels and postoperative changes in BNP levels for
ostoperative outcome.
aterials and Methods
e conducted a prospective cohort study in the Pediatric Cardiac
ntensive Care Unit at the University of California, San Francisco
hildren’s Hospital, between June 2005 and June 2006. Eligible
atients were neonates with congenital cardiac defects undergoing
urgical repair or palliation using cardiopulmonary bypass (CPB).
atients were excluded from the study if their weight was less than
kg or if they were less than 36 weeks postconceptual age at
urgery.
The preoperative anesthesia management, intraoperative by-
ass strategy, and subsequent Pediatric Cardiac Intensive Care
nit management followed standard institutional practices. All
atients underwent modified ultrafiltration before separating from
PB. An on-service team, blinded to the BNP values, made all
atient management decisions.
We obtained written informed consent from the patients’ par-
nts or guardians before enrollment in the study. The University of
alifornia, San Francisco review board approved the study.
atient Classification
e divided the patients into 2 groups. Group I consisted of
eonates who underwent palliation with a modified stage I Nor-
ood procedure, and group II consisted of neonates who under-
ent biventricular repair.
ata Collection
lood samples were obtained from an arterial catheter preopera-
ively and at 2, 12, and 24 hours after CPB. In patients unable to
eparate from CPB postoperatively, preoperative but not postop-
rative samples were obtained because of the potential confound-
ng effects of extracorporeal life support. The samples were
laced immediately on ice in chilled ethylenediamine tetraacetic
Abbreviations and Acronyms
AVdO2  arteriovenous oxygen saturation difference
BNP  B-type natriuretic peptide
CPB  cardiopulmonary bypass
LCOS  low cardiac output syndrome
SvO2  venous oxyhemoglobin saturationcid tubes and centrifuged at 3000 rpm for 15 minutes at 4°C. C
40 The Journal of Thoracic and Cardiovascular Surgery ● Octoeparated plasma was stored at20°C. Within 4 days of obtaining
he sample, the plasma was thawed to room temperature and BNP
evels were measured using a commercially available fluorescence
mmunoassay (Triage Meter Plus, Biosite Diagnostic, San Diego,
alif). The measurable range of BNP on this device is between 5
nd 5000 pg/mL. The estimated coefficient of variation for the
ssay is 9.2% to 11.4%.
Clinical and biochemical data were collected prospectively at
ach sampling point and daily thereafter by an observer blinded to
he BNP data. The clinical data collected included the patient
emographics, CPB duration, aortic crossclamp duration, inotrope
ose, mean systemic arterial pressure, central venous pressure,
eart rate, intensive care unit days, hospital days, and use of
echanical ventilation. Biochemical data collected included he-
atocrit, arterial and venous blood gases, serum lactate, blood urea
itrogen, and creatinine. The occurrence of cardiac transplant was
onitored for 6 months after surgery.
utcome Measures
he primary end point was the occurrence of a poor postoperative
utcome, within 6 months of surgery, defined as (1) death, (2) the
eed for an unplanned cardiac operation before discharge, or (3)
he need for a cardiac transplant during the 6-month follow-up
eriod.
Secondary end points were the duration of mechanical venti-
ation and the development of LCOS within 48 hours after surgery.
he duration of mechanical ventilation was quantified as the
umber of ventilator-free days within the first 30 days after sur-
ery. The definition of LCOS was derived from criteria published
y Hoffman and colleagues,9 which included a combination 
hanges in clinical signs and laboratory indicators. Criteria in-
luded tachycardia, oliguria, poor perfusion, cardiac arrest, or
etabolic acidosis, and the need for interventions aimed at aug-
enting cardiac output, such as increased pharmacologic support
elative to the baseline and mechanical pacing.
alculations
notrope use was quantified by a score adapted from Wernovsky
nd colleagues.10 The score was calculated from the level
notropic support the patients were receiving (in micrograms/
ilogram/minute) at each sampling point according to the follow-
ng equation: dopamine  dobutamine  [(epinephrine  norepi-
ephrine)  100]  (milrinone  20). The arteriovenous oxygen
aturation difference (AVdO2) was calculated as the co-oximetric
rterial oxyhemoglobin saturation minus the central venous oxy-
emoglobin saturation (SvO2).
ata Analysis
ifferences in the continuous variables between groups were
ested with the Student t test or Mann–Whitney U test. Differences
n the categoric variables between groups were tested with the
isher exact test. Contingency tables were formulated to determine
he sensitivity and specificity of BNP measurements. Correlations
etween variables were performed by Spearman rank correlation
ethod. Changes in BNP over time were compared by repeated-
easures analysis of variance. Statistical analyses were performed
ith the use of Prism 4.0 (GraphPad Software, Inc, San Diego,



































































hirty-nine consecutive neonates were enrolled in the study
group I: 16, group II: 23). Three patients in group II could
ot be separated from CPB after surgery. Therefore, 36
atients (group I: 16, group II: 20) had complete BNP
easurements. The patients’ preoperative characteristics
re shown in Table 1. The patients’ ages ranged from
0 days (mean 10  8 days). Group I was younger than
roup II at the time of surgery (7 4 days vs 12 10 days,
 .03). The mean preoperative serum lactate was lower in
roup I than that in group II (1.4 0.4 mmol/L vs 1.9 0.7
mol/L, P  .02, Table 1).
The patients’ intraoperative and postoperative character-
stics are shown in Table 2. The inotrope score 24 
fter surgery tended to be higher in group I than in group II
P  .05).
utcomes
here were 6 patients (15%) who had a poor postoperative
utcome. Of the 36 patients who had complete postopera-
ive BNP data available, 5 (14%) had a poor postoperative
utcome. Between groups, 3 of 16 patients (19%) in group
ABLE 1. Preoperative demographics of all patients
Group
atients 16
ge, d 7  4
eight, kg 3.3 0
ale, n (%) 6 (38%
ype of surgery Norwood operation*
ype of cardiac lesion 11 HLHS
1 DORV, HRV, HAA
1 Tricuspid atresia, TG
1 IAA, HAA
1 AVSD, hypoplastic le
1 TGA, HAA
eart rate, min1 150 1
ean arterial pressure, mm Hg 48 6
rterial oxygen saturation, % 92 6
echanical ventilation use, n (%) 13 (81%
rostaglandin E1 use, n (%) 16 (100%
erum lactate, mmol/L 1.4 0
ematocrit, % 40 5
lood urea nitrogen, mg/dL 15.7 9
lood creatinine, mg/dL 0.7 0
LHS, Hypoplastic left heart syndrome; DORV, double outlet right vent
trioventricular septal defect; TGA, transposition of great arteries; IAA, inte
APVR, total anomalous pulmonary venous return; TA, truncus arteriosus;
tandard deviation or number (percentage). *Fourteen with right ventricle-p, and 3 of 23 patients (13%) in group II had a poor p
The Journal of Thoracicto
s
ostoperative outcome (Table 2). The characteristics 
atients with a poor postoperative outcome are shown in
able 3.
The number of ventilator-free days was similar between
roups (23  5 days vs 24  8 days, Table 2). LCO
Group II P
23

















49  9 .59




37  6 .18
11.6 7.5 .13
0.6 0.2 .26
HRV, hypoplastic right ventricle; HAA, hypoplastic aortic arch; AVSD,
ion of aorta; IVS, intact ventricular septum; VSD, ventricular septal defect;
tetralogy of Fallot; PA, pulmonary atresia. Data are presented as mean 
nary artery conduits and 2 with modified Blalock-Taussig shunts. †n  14.





(n  23) P
PB time, min 139 32 130 47 .50
rossclamp time, min 50 14 58 27 .27
4-h inotrope score 13.4 5.1 9.0  7.6* .05
4-h serum lactate, mmol/L 2.3 1.1 2.0 1.3† .41
CU length of stay, d 14 9 10  8 .10
ospital length of stay, d 25 9 21  12 .32
entilator-free days, d 23 5 24  8 .75
COS, n (%) 10 (63%) 7 (35%)* .18
equirement of ECLS 1 (6%) 3 (13%) .63
oor outcomes, n (%) 3 (19%) 3 (13%) .67
PB, Cardiopulmonary bypass; ICU, intensive care unit; LCOS, low cardiac
utput syndrome; ECLS, extracorporeal life support. Data are presented as











ricle;atients with ECLS initiated in the operating room. †n  19.
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Developed in 17 patients (44%) within the first 48 hours
fter surgery (Table 2). Of the 36 patients who had com
ostoperative BNP data available, 17 (47%) had postoper-
tive LCOS. The occurrence of LCOS was not different
etween groups; postoperative LCOS developed in 10 of 16
atients (63%) in group I and in 7 of 20 patients (35%) in
roup II (Table 2).
erioperative B-type Natriuretic Peptide Levels
NP levels preoperatively and at 2, 12, and 24 hours post-
peratively for all patients are shown in Figure 1. 
evels decreased after surgery; BNP levels at 12 hours were
ignificantly lower than preoperative levels (P  .01), and
NP levels at 24 hours were significantly lower than levels
t all other sample times (P  .001). BNP levels for groups
 and II are shown in Table 4.
igure 1. Column bar plots showing the change in BNP before
nd after CPB. The mean (columns) and the standard error (ver-
ical lines). Twenty-four– hour postoperative BNP levels are sig-
ificantly lower than preoperative, 2-hour, and 12-hour BNP
ABLE 3. Characteristics of patients with poor outcomes
atient Group Diagnosis Surgery
1 I HLHS Modified Norwood
2 I HLHS Modified Norwood
3 I AVSD, HAA, LV
hypoplasia
Modified Norwood
4 II TAPVR Repair of TAPVR
5 II DORV VSD closure, RVOT reconstructio
6 II HAA, VSD VSD closure, aortic arch repair
LHS, Hypoplastic left heart syndrome; AVSD, atrioventricular septal def
eturn; DORV, double outlet right ventricle; VSD, ventricular septal defect; EC
ight ventricular outflow tract; OR, operating room; RV, right ventricle
easurements of BNP because ECLS was initiated in the operating roompevels. *P < .01. **P < .001. BNP, B-type natriuretic peptide.
42 The Journal of Thoracic and Cardiovascular Surgery ● Octoe
reoperative B-type Natriuretic Peptide Levels
nd Outcomes
reoperative BNP levels correlated with postoperative BNP
evels at 2 hours (rho  0.64, P  .0001) but not at 12 and
4 hours. There was no association between preoperative
NP levels and age, sex, weight, preoperative mean arterial
ressure, heart rate, and arterial oxygen saturation, or pre-
perative hematocrit, serum lactate, blood urea nitrogen,
nd creatinine. In addition, preoperative BNP levels were
ot correlated with the number of ventilator-free days, in-
ensive care unit stay, or days of hospitalization.
Preoperative BNP levels were not different between pa-
ients with or without postoperative LCOS or between pa-
ients with or without poor postoperative outcome.
ostoperative B-type Natriuretic Peptide Levels
nd Outcomes
n the 36 patients with postoperative BNP measurements,
4-hour BNP levels correlated with heart rate (rho  0.47,
 .004) and inotrope score (rho 0.46, P .005). There
as no correlation between postoperative BNP levels and
ean arterial pressure, central venous pressure, arterial ox-
gen saturation, or hematocrit, serum lactate, AVdO2, blood
rea nitrogen, creatinine, or duration of CPB. In addition,
ostoperative BNP levels did not correlate with intensive
are unit or hospital length of stay.
Postoperative BNP levels did not correlate with the num-
er of ventilator-free days and were not different between
atients with or without postoperative LCOS. In addition,
ostoperative BNP levels were not different between pa-
ients with or without poor postoperative outcome.
erioperative B-type Natriuretic Peptide Change
nd Outcomes
ecause absolute BNP levels are age and lesion-specific, we
xamined the relationship between the change in BNP over
he first 24 hours after surgery and outcomes. Of the 36
Major poor outcome
eath at POD 13, with ECLS initiated 42 h postoperatively
equiring transplant because of persistent RV dysfunction 4
months after operation
eoperation at POD 3 for residual aortic arch obstruction
eoperation at POD 10 for residual pulmonary venous obstruction
eath at POD 35
eath at POD 14, with ECLS initiated in the OR because of
inability to separate from CPB*
AA, hypoplastic aortic arch; TAPVR, total anomalous pulmonary venous
xtracorporeal life support; POD, postoperative day; LV, left ventricle; RVOT,
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Devel was lower than the preoperative BNP level (24-h/pre
NP ratio  1) in 29 patients (81%) (group I: 14 of 16,
8%; group II: 15 of 20, 75%, P  .43). However, in 7
atients (19%), BNP levels at 24 hours were increased
bove preoperative levels (24-h/pre BNP ratio  1). The
haracteristics of patients with a 24-hour/pre BNP level less
han 1 and patients with a 24-hour/pre BNP level of 1 or
ore are shown in Table 5. LCOS developed within the
8 hours after surgery in all 7 patients (100%) with a
4-hour/pre BNP level of 1 or more compared with only 10
f 29 patients (34%) with a 24-hour/pre BNP level less than
(P  .002, Table 5).
In addition, compared with patients with a 24-hour/pre
NP level less than 1, patients with a 24-hour/pre BNP level
f 1 or more had significantly fewer ventilator-free days (17
ays  13 vs 26 days  3, P  .002, Table 5).
Finally, only 1 of 29 patients (3%) with a 24-hour/pre
NP level less than 1 experienced a poor postoperative
ABLE 4. B-type natriuretic peptide levels at different tim
Pre BNP (pg/mL) 2-h BNP (pg
roup I (n  16) 1866  1019 (698-3450) 1550 916 (32
roup II (n  23)† 1617  1414 (8-5000) 1350 881 (58
NP, B-type natriuretic peptide. Data are presented as mean  standard
4 hours, excluding 3 patients with ECLS initiated in the operating room.
ABLE 5. Characteristics of patients with a 24-hour/pre
-type natriuretic peptide ratio of 1 or greater and patients







ratio > 1) P
atient number 29 7
ge, d 9 6 12  12 .40
eight, kg 3.3  0.5 3.5  0.7 .36
ale, n (%) 16 (55%) 4 (57%) 1.0
roup I, n (%) 14 (48%) 2 (29%) .43
PB time, min 136 36 121  59 .39
rossclamp time, min 54 25 46  19 .41
4-h inotrope score 9.9 6.5 14.8 7.1 .07
4-h serum lactate, mmol/L 2.1 1.0* 3.1  1.9† .20
CU length of stay, d 10 8 16  14 .69
ospital length of stay, d 23 11 25  13 .58
entilator-free day, d 26 3 17  13 .002
COS, n (%) 10 (34%) 7 (100%) .002
oor outcome, n (%) 1 (3%) 4 (57%) .003
1 reoperation 2 deaths
1 transplant
1 reoperation
NP, B-type natriuretic peptide; CPB, cardiopulmonary bypass; ICU, inten-
ive care unit; LCOS, low cardiac output syndrome. Data are presented as*ean  standard deviation. *n  28. †n  5.
The Journal of Thoracicst
utcome, compared with 4 of 7 patients (57%) with a
4-hour/pre BNP level of 1 or more (P  .003, Table 5)
he postoperative changes in BNP over time (expressed as
he postoperative to preoperative BNP ratio) are shown for
atients with and without poor postoperative outcomes in
igure 2. There was a significant interaction between 
ome and sample time (P  .0001). The postoperative to
reoperative BNP ratio was greater in patients with poor
ostoperative outcome than in patients without poor post-
perative outcome at 2, 12, and 24 hours after surgery
Figure 2). A 12-hour/pre BNP level of 1 or more 
ensitivity of 80% and a specificity of 77% for predicting
oor postoperative outcome (P  .02), and a 24-hour/pre
NP level of 1 or more had a sensitivity of 80% and a
pecificity of 90% for predicting a poor postoperative out-
ome (P  .003).
VdO2 and Lactate
e examined the relationship between AVdO2 and serum
actate at each sampling point and outcome. There was no
ssociation between either the AVdO2 or serum lactate
evels with the number of ventilator-free days or the occur-
ence of poor postoperative outcome. In addition, postop-
rative changes in serum lactate were not associated with
utcome.
igure 2. Comparisons of postoperative changes of BNP ratio
ver time between patients with good outcomes (n  31) and
atients with poor outcomes (n  5). The BNP ratios are greater
t all sample times in the poor outcome group. The scale of y-axis
s log transformed. Data are presented as mean standard error.
ints
12-h BNP (pg/mL) 24-h BNP (pg/mL) P*
0) 1362 832 (543-3060) 638 353 (38-1340) .0001
) 1043 667 (152-2388) 463 239 (91-988) .0001
tion and range. *Analysis of variance within groups. †n  20 in 2, 12, ande po
/mL)
1-372
-2850P < .05 versus good outcome. BNP, B-type natriuretic peptide.









































































































hese data suggest that BNP may be a valuable biomarker
or prognostication and risk stratification in neonates under-
oing cardiac surgery. We found that an increase in BNP
evels above the preoperative baseline over the first 24 hours
fter surgery was associated with LCOS and an increased
uration of mechanical ventilation, and predicted the com-
osite end point of death, an unplanned cardiac operation
efore discharge, or a cardiac transplant within the 6-month
ollow-up period.
In a study of infants and children with biventricular
ardiac defects, we previously reported8 that BNP level
ncreased after surgery and that the 12-hour level was as-
ociated with the need for mechanical ventilation beyond 48
ours and the development of LCOS. In contrast, the current
tudy did not find an association between absolute BNP
evels and the primary or secondary outcomes. This may
elate to the wide variability in BNP levels found in neo-
ates (Table 4). Several studies suggest that this variab
s influenced in part by the age, type of cardiac defect, and
xposure to CPB.6,11-13 Because we anticipated that pote-
ial associations between absolute BNP levels and outcomes
ould be difficult to demonstrate given this variability, we
lso studied the predictive value of the postoperative change
n BNP. Moreover, because BNP levels likely are altered by
echanisms intrinsic to the myocardium, we hypothesized
hat perioperative alterations in BNP would capture cardio-
ulmonary derangements, particularly those resulting in
ong-term sequelae, in a unique manner. We found that
ean BNP levels decreased in the majority of neonates after
urgery, in contrast with other studies.8,12,14,15 In the presen
tudy, only 1 patient with a postoperative decrease in BNP
rom preoperative baseline had a poor postoperative out-
ome, whereas an increase in BNP above baseline after
urgery was associated with LCOS, an increased duration of
echanical ventilation, and a poor postoperative outcome.
The mechanisms regulating BNP in neonates with con-
enital cardiac defects undergoing surgery remain to be
larified. Developmental studies in healthy subjects indicate
hat BNP levels are highest at birth but decrease by the first
eek of life, and by 2 weeks of age are generally lower than
dult levels.11,16 Preoperative BNP levels in the prese
tudy were more than 10-fold greater than the normal re-
orted values for neonates and were also much greater than
evels reported in infants and children with congenital car-
iac defects.8,11,14,16-18 One potential mechanism for t
ecrease in BNP after surgery is a reduction in the Qp:Qs
atio. A linear relationship between BNP levels and the
p:Qs ratio in patients with ventricular septal defects has
een reported.19 In addition, in cardiac defects associat
ith an obstruction to outflow from the heart, surgical
orrection or palliation may have reduced the pressure load
laced on the ventricle, thus decreasing BNP release. In a
44 The Journal of Thoracic and Cardiovascular Surgery ● Octoact, a recent study found that BNP levels correlated with
he degree of left ventricular outflow tract obstruction in
hildren and that they decreased 24 hours after successful
alloon valvotomy in newborns with aortic stenosi20
iven that numerous studies have demonstrated an increase
n BNP after CPB, it is unclear whether surgical palliation
r repair of the cardiac defects allowed BNP levels to
ecrease despite the effect of CPB, or whether the response
o CPB differs in neonates in a manner that mitigates against
n increase in BNP.8,12,14,15
We found similar changes in BNP levels between neo-
ates undergoing a modified Norwood Stage I operation and
biventricular repair, in contrast with studies of levels in
lder children.17 Although BNP levels in group I tended
e higher than group II in our study, we found a similar
ostoperative decrease in BNP in both groups. We did not
nd significant outcome differences between groups, de-
pite the increased risks traditionally associated with the
odified Norwood stage I procedure.
To date, the 2 most commonly used biomarkers in the
anagement of patients after congenital cardiac surgery are
he SvO2 (or AVdO2) and serum lactate.1,21-24 Determina-
ions of SvO2 and the AVdO2 are relatively reliable indica-
ors of the cardiac output at any given time and thus have
een used successfully to guide postoperative therapie21
everal studies on serum lactate have found that lactate,
specially its rate of change in the postoperative period,
redicted outcome, including mortality.1,22 Unfortunately,
hese findings have not been reproduced by other larger
tudies, and the precise lactate levels that were predictive in
he positive studies varied considerably, which has obviated
standardized use of lactate as a prognostic biomar-
er.1,22-24 However, because acute management decisio
re aimed at normalizing the SvO2 and lactate levels, it is
ikely that only persistently abnormal values refractory to
reatment will be predictive of an adverse event in the short
erm. Therefore, it is not surprising that SvO2, AVdO2, and
oth absolute serum lactate levels and postoperative
hanges in serum lactate failed to predict postoperative
utcome in the current study. The relationship of these
actors to LCOS could not be evaluated, because they con-
ributed to its clinical definition.
We used the duration of mechanical ventilation as a
econdary outcome measure because it is often used as a
urrogate marker of disease severity in various clinical
tudies. We chose to analyze the duration of mechanical
entilation as ventilator-free days over the first 30 postop-
rative days to avoid confounding the analysis with patients
ho died or were transferred to a transplant center while
eceiving mechanical ventilation. Because validated criteria
or weaning from mechanical ventilation are not available
or neonates after repair of congenital cardiac defects, the
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Dasis. It is important to note that these physicians were
linded to the BNP values.
We also used the development of LCOS as a secondary
utcome, because it has been used as an end point in
herapeutic trials in pediatric patients after cardiac surge9
lthough postoperative LCOS developed in all patients
ith a 24-hour/pre BNP ratio of greater than 1, the majority
f LCOS cases developed early in the postoperative course
efore the 24-hour time point. Thus, the perioperative
hange in BNP did not predict LCOS but rather was asso-
iated with it. Whether goal-directed therapies for LCOS
hat target postoperative changes in BNP could be used in
eonates after cardiac surgery was not evaluated but war-
ants further study. For instance, our study suggests that
eonates with an increase in BNP levels at 24 hours com-
ared with baseline should undergo intense scrutiny to detect
nd treat any residual hemodynamic lesions, including occult
r overt heart failure with close follow-up for 6 months.
The primary limitation of the present study relates to
ample size. Larger studies will be needed to precisely
efine the role of BNP in the management of neonates with
ardiac disease. Moreover, given the considerable variation
etween patients, larger longitudinal studies are needed to
valuate BNP in each cardiac defect and at exact develop-
ental time points.
onclusions
e found that mean BNP levels decreased over the first 24
ours in the majority of neonates after cardiac surgery.
owever, an increase in BNP levels above preoperative
aseline at 24 hours was associated with LCOS and pro-
onged mechanical ventilation, and predicted death, an un-
lanned operation, or cardiac transplant with a sensitivity of
0% and specificity of 90%.
The authors thank Megan Tracey, PNP, Julie Bushnell, PNP,
aura Presnell, ACNP, the Pediatric Critical Care Fellows, the
ardiac Intensive Care Nurses, the Pediatric Clinical Research
enter, Adam Gorham, and Leslie Kurkjian for their invaluable
ssistance with the study.
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